p57kip2在肝癌组织中的表达及其与临床病理因素、PCNA和p53的关系

目的:检测细胞周期抑制因子p57kip2在肝癌中的表达水平,探讨它与临床病理因素、增殖细胞核抗原(PCNA)、p53的关系. 方法:用免疫组织化学法检测32例肝癌组织和10例正常肝脏组织中p57kip2, PCNA和p53的表达水平. 结果:p57kip2在肝癌组织中的阳性率56.2%,显著低于正常肝脏组织(100%)(P=0.011),p57kip2的缺失表达与肝癌细胞的分化较差(P=0.007)、临床分期较晚(P=0.041)及预后较差有关(P=0.036),与年龄、AFP, 肿瘤大小及肿瘤侵犯转移无显著相关(P>0.05);PCNA在肝癌组织中阳性率为56.2%,与p57kip2的表达有关(P=0.036);p53在肝癌组织中的阳性率46.9%,与p57kip2表达在统计学上无相关性(P>0.05). 结论:肝癌组织中存在p57kip2的表达缺失、PCNA的高表达, 共同参与肝癌的发生、发展,而p57kip2和p53可能通过不同途径来诱导细胞凋亡.

Expression of p57kip2 and its relationships with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma

AIM: To investigate the expression of p57 kip2 and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma (HCC). METHODS: Expression of p57 kip2 , PCNA and p53 in tumor tissues from 32 patients with HCC and 10 liver tissues of normal persons was detected with Elivision immunohistochemical technique. RESULTS: p57 kip2 protein positive expression rate in HCC was 56.2%,which was lower than that in normal tissues (100%) ( P =0.011). The reduced expression of p57 kip2 protein correlated significantly with moderate or low differentiation of tumor cells ( P =0.007), high clinical stage ( P =0.041) and poor prognosis ( P =0.036), but did not correlate significantly with metastasis, tumor size, level of AFP and age ( P >0.05). PCNA positive expression rate was 56.2%, which was correlated significantly with the expression of p57 kip2 ( P =0.036) and p53 positive expression rate was 46.9%, which was not correlated significantly with the expression of p57 kip2 ( P >0.05). CONCLUSION: There is a marked loss or absence of p57 kip2 expression and high expression of PCNA in HCC, which are involved in the carcinogenesis and development of HCC. p57 kip2 and p53 may induce apoptosis via different mechanisms.